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ABSTRACT

47

Background: Emerging evidence suggests that increasing intakes of nitrate-rich vegetables

48

may be an effective approach to reducing blood pressure.

49

Objective: Our primary aim was to determine whether daily consumption of nitrate-rich

50

vegetables over 4 weeks would result in lower blood pressure.

51

Design: Thirty participants with pre-hypertension or untreated grade 1 hypertension were

52

recruited to a randomised, controlled, crossover trial with 4-week treatment periods separated

53

by 4-week washout periods. Participants completed three treatments in random order: (1)

54

increased intake (~200 g/d) of nitrate-rich vegetables (high nitrate, HN, ~150 mg/d nitrate);

55

(2) increased intake (~200 g/d) of nitrate-poor vegetables (low nitrate, LN, ~22 mg/d nitrate);

56

and (3) no increase in vegetables (control, C, ~6 mg/d nitrate). Compliance was assessed

57

using food diaries and by measuring plasma nitrate and carotenoids. Nitrate metabolism was

58

assessed using plasma, salivary, and urinary nitrate and nitrite concentrations. The primary

59

outcome was blood pressure assessed using 24-hour ambulatory, home, and clinic

60

measurements. Secondary outcomes included measures of arterial stiffness.

61

Results: Plasma nitrate and nitrite concentrations were increased with the HN treatment in

62

comparison to the LN and control treatments (P<0.001). Plasma carotenoids were increased

63

with the HN and LN treatments compared to the control (P<0.01). High nitrate treatment did

64

not reduce systolic blood pressure (24-hour ambulatory: HN 127.4±1.1 mmHg, LN 128.6±1.1

65

mmHg, C 126.2±1.1 mmHg, P=0.20; home: HN 127.4±0.7 mmHg, LN 128.7±0.7 mmHg, C

66

128.3±0.7 mmHg, P=0.36; clinic: HN 128.4±1. 3mmHg, LN 130.3±1.3 mmHg, C 129.8±1.3

67

mmHg, P=0.49) or diastolic blood pressure compared with LN and C treatments (P>0.05)

68

after adjustment for pre-treatment values, treatment period and treatment order. Similarly, no

69

differences were observed between treatments for arterial stiffness measures (P>0.05).
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Conclusion: Increased intake of nitrate-rich vegetables did not lower blood pressure in pre-

71

hypertensive or untreated grade 1 hypertensive individuals when compared with increased

72

intake of nitrate-poor vegetables and no increase in vegetables.

73

Clinical trial registry number and website: This trial was prospectively registered at

74

www.anzctr.org.au as ACTRN12615000194561.

75

Keywords: blood pressure, vascular stiffness, nitrate, vegetables, hypertension

5
76

INTRODUCTION

77

High blood pressure is the leading risk factor for global disease burden (1). The maintenance

78

of a healthy blood pressure and the prevention of hypertension continues to be a public health

79

priority worldwide (2, 3). It is estimated that for every 10 mmHg reduction in systolic blood

80

pressure there is a 13-28% lower risk of cardiovascular disease events and all-cause mortality

81

(4). Arterial stiffness, which is closely related to hypertension (5, 6), is also a predictor of

82

cardiovascular and all-cause mortality (7). Diets rich in vegetables, such as the vegetarian diet

83

(8), Mediterranean diet, Nordic diet, and Dietary Approaches to Stop Hypertension (DASH)

84

diet (9), have been shown to lower blood pressure. There are many components of a diet rich

85

in vegetables that may benefit cardiovascular health. In particular, emerging evidence

86

suggests that inorganic nitrate found in vegetables can contribute to lowering blood pressure

87

(10, 11).

88

Inorganic nitrate is a precursor for nitric oxide (NO) (12). Nitric oxide is an important cell

89

signalling molecule and potent vasodilator critical for vascular health (13). The enterosalivary

90

nitrate-nitrite-NO pathway generates NO via the sequential reduction of the anions nitrate and

91

nitrite. This is facilitated by facultative anaerobic bacteria in the oral cavity, the acidic

92

environment of the stomach and numerous endogenous molecules identified as having nitrite

93

reducing ability (14). Increased scavenging of NO and dysfunction of the L-arginine-NO

94

pathway underlie the reduced bioavailability of NO observed in hypertensive individuals (15).

95

Increasing plasma nitrate through dietary means may provide a new therapeutic measure for

96

restoring NO levels.

97

Vegetables account for approximately 80% of total nitrate consumed in the general

98

population, with the majority coming from leafy green vegetables and beetroot (12, 16). There

99

is now consistent and convincing evidence that an increase in nitrate salts and nitrate-rich

100

vegetables can result in a decrease in blood pressure within hours of ingestion (10, 11, 17-19).
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However, data from short-term trials are yet to provide a clear understanding of the effects of

102

a chronic increase in nitrate intake on blood pressure (10). In particular, there is a need to

103

determine whether increasing nitrate-rich vegetables results in sustained lower blood pressure

104

in individuals with elevated blood pressure. The results of published studies in this population

105

are inconsistent (19, 20).

106

The objective of this study was to investigate whether increased intake of nitrate-rich

107

vegetables would result in lower blood pressure and improved arterial stiffness. An increased

108

intake of nitrate-rich vegetables was compared with a matching increase in nitrate-poor

109

vegetables, and no increase in vegetables.
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METHODS

111

Ethics

112

The Vegetable Intake and Blood Pressure (VIABP) study (registered at www.anzctr.org.au as

113

ACTRN12615000194561) was approved by the University of Western Australia Human

114

Research Ethics Committee and was carried out in accordance with the Declaration of

115

Helsinki. Written informed consent was obtained from all participants.

116

Trial design

117

The VIABP study was a randomised, controlled, crossover trial with three 4-week treatment

118

periods, each preceded by a 4-week washout period (Supplemental Figure 1). The study was

119

conducted at the Royal Perth Hospital Medical Research Foundation, Perth, Australia.

120

Participants were randomly assigned to one of six sequence orders for the three treatments

121

using computer-generated random numbers, assigned upon randomisation. The three

122

treatments were: (1) increased intake of nitrate-rich vegetables (high nitrate diet, ~200 g/d);

123

(2) increased intake of nitrate-poor vegetables (low nitrate diet, ~200 g/d); and (3) no increase

124

in vegetables (control diet). Throughout the entire 24-week trial period all participants were

125

asked to limit their intake of nitrate-rich vegetables, except whilst undertaking the high nitrate

126

treatment (Supplemental Table 1).

127

Participants

128

Thirty participants with pre-hypertension or untreated grade 1 hypertension were recruited

129

from the Perth general population using newspaper advertisements between March and July

130

2015. Participants were ambulant men and women between the ages of 21 and 75 years, with

131

a resting mean systolic blood pressure between 120-160 mmHg, inclusive. Participants were

132

excluded if they were: diabetic; a smoker; taking antihypertensive medication, nitric oxide

133

donors, organic nitrates and nitrites, or related drugs; had a body mass index (BMI) ≥35 kg/m2

134

or <18.5 kg/m2; or used antibacterial mouth wash. For a complete list of inclusion and
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exclusion criteria see Supplemental Table 2. Participants underwent screening procedures

136

consisting of anthropometric measurements (height, weight, waist circumference, and hip

137

circumference), an electrocardiogram, and a fasting blood test, which consisted of a full blood

138

count, lipid profile, and glucose test, analysed by PathWest laboratories (Royal Perth

139

Hospital, Perth, Australia). Blood pressure was assessed using a Dinamap 1846SX/P

140

oscillometric recorder (Critikon Inc., Tampa, FL, USA). Participants were asked to rest for 5

141

minutes before five blood pressure and heart rate readings were taken at 2 minute intervals.

142

The first measurement was excluded and the mean of the next four consecutive readings was

143

used to determine resting blood pressure. After blood tests confirmed eligibility, participants

144

were asked to return to the research clinic to complete a medical examination by one of our

145

physicians (IBP and LJB). Participants provided a list of current medications and

146

supplements, and a medical history. At the same visit, participants completed a validated food

147

frequency questionnaire (Dietary Questionnaire for Epidemiological Studies Version 2,

148

DQES v2) (21-23) to obtain baseline dietary intake. Participants were supervised by a

149

nutritionist whilst completing the questionnaire. Food models, food charts, measuring cups,

150

and measuring spoons were provided to ensure the accuracy of reported food consumption.

151

Dietary interventions

152

During each 4-week treatment period, additions were made to participants’ breakfast and

153

dinner, consisting of vegetables blended into juices or a matching control juice. Participants

154

were asked to maintain all meals as usual with the exception of limiting high nitrate

155

vegetables where possible. In the high and low nitrate treatment periods participants were

156

asked to consume 100 g/d of high and low nitrate vegetables, respectively, before breakfast

157

and dinner. This was equivalent to increasing vegetable intake by approximately 2.7 serves/d

158

(~200-300 kJ/d) (24). For the control treatment, participants were asked to blend a quarter of

159

an orange and 8 g maltodextrin in water (approximately energy matched to the vegetables

9
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consumed in the high and low nitrate treatments). Prior to randomisation, participants

161

consumed a sample juice for all three treatments and completed a juice acceptability

162

questionnaire to ensure willingness to participate. They were provided with blenders and

163

blended at least three different vegetables of approximate equal weight with a quarter of an

164

orange (for taste) and less than 1 cup (~200 ml) of water. For the low nitrate treatment,

165

participants were instructed they could microwave, oven bake, boil, or steam any low nitrate

166

root vegetables before consumption, and were asked not to add any condiments (e.g. cooking

167

oil, salt). The high and low nitrate vegetables consumed by participants are presented in

168

Supplemental Table 3. Participants were asked to freeze a small sample of each treatment

169

juice in a sterile 5 ml tube in the week prior to their post-treatment visit. Nitrate and nitrite

170

concentrations were determined for each treatment juice. In addition, participants kept a diary

171

of the type and weight of all vegetables (high nitrate and low nitrate) consumed in all

172

prepared juices. Treatment diaries along with plasma concentrations of nitrate, nitrite, and

173

total carotenoids were used to assess compliance.

174

Clinical measurements

175

Anthropometric measurements (body weight, waist circumference, and hip circumference)

176

were assessed pre- and post-treatment. Participants were wearing minimal clothing and no

177

shoes. Standing height (m) was measured without shoes using a wall-mounted stadiometer to

178

the nearest 0.01 m. Fasting body weight (kg) was measured without shoes using electronic

179

scales to the nearest 0.01 kg. Waist and hip circumference (cm) were measured using a steel

180

tap measure (Lufkin Executive Thinline, W606PM, USA). Waist and hip measurements were

181

used to calculate waist-to-hip ratio (waist cm / hip cm).

182

Physical activity was assessed pre- and post-treatment using the validated short form of the

183

International Physical Activity Questionnaire (IPAQ) (25). Total physical activity was

184

calculated in MET-min/week and then converted to kJ/d. Alcohol intake was assessed pre-
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and post-treatment using a 7 day alcohol diary. Standard drinks were calculated by

186

multiplying the volume of alcohol consumed (L), the percentage of alcohol consumed (%)

187

and the specific gravity of ethyl alcohol (0.789). Alcohol was converted to g/d.

188

Blood pressure

189

Ambulatory blood pressure

190

Ambulatory blood pressure and heart rate were monitored every 20 minutes during the day

191

and every 30 minutes overnight for a 24-hour period commencing at the end of pre- and post-

192

treatment visits, as previously described (26). Measurements showing an error code or those

193

with a pulse pressure of less than 20 mmHg were excluded from the analysis. Blood pressure

194

traces that were missing more than four hourly means over the 24 hours were also excluded

195

from the analysis. A minimum of 70% successful readings was considered a valid recording.

196

Mean blood pressure was determined for the 24-hour, daytime (06:00-21:59), and night-time

197

(22:00-05:59) period.

198

Home blood pressure

199

Participants were provided with a digital blood pressure monitor (UA-767PC, A&D Co., Ltd,

200

Saitama, Japan) and an appropriately sized upper-arm cuff. Participants were given

201

appropriate training and instructions on its use prior to the study commencing. Home blood

202

pressure was measured and recorded by each participant three times daily (shortly after

203

waking and prior to breakfast, 1-2 hours prior to dinner, and 1-2 hours after dinner) for the

204

entire study duration. Participants were instructed to rest for 5 minutes prior to commencing

205

three blood pressure readings over a 3-minute period. The first measurement was excluded

206

from the analysis and the mean of the second and third measurements used. Mean blood

207

pressure was determined for the overall 4-week pre- and post-treatment periods; week 1, week

208

2, and week 3 of each treatment; the last 7 days pre- and post-treatment period; and the

209

morning, afternoon, and evening of the last 7 days pre- and post-treatment period.
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Clinic blood pressure

211

Clinic blood pressure was measured pre- and post-treatment using the SphygmoCor XCEL

212

device (2012 AtCor Medical Pty. Ltd., Sydney, Australia). An appropriately sized blood

213

pressure cuff was fitted to each participant’s non-dominant arm approximately 2.5 cm above

214

the antecubital fossa. Participants were fasting for at least 12 hours and were asked to rest in a

215

supine position for 5 minutes prior to three blood pressure measurements performed at 60

216

second intervals. The first blood pressure reading was excluded and the mean of the second

217

and third measurements used in analysis.

218

Arterial stiffness

219

Pulse wave analysis (PWA) and pulse wave velocity (PWV) were measured pre- and post-

220

treatment using the SphygmorCor XCEL device (2012 AtCor Medical Pty. Ltd., Sydney

221

Australia). Participants were fasting for at least 12 hours, and avoided vigorous exercise and

222

alcohol intake for at least 24 hours prior to assessment. Participants were asked to rest for 5

223

minutes in a supine position before three blood pressure measurements at 60 second intervals

224

were taken. Clinic blood pressure was followed by one 10 second capture PWA reading,

225

which included central aortic systolic pressure, central aortic diastolic pressure, and

226

augmentation index (%). An appropriately sized cuff was then fitted to the participants’ right

227

thigh. Tubing was attached and a probe placed on the carotid artery. When a pulse was

228

detected the femoral cuff inflated and captured aortic PWV. Two PWV measurements were

229

taken and the average used in the analysis. If a >0.5 m/s difference between the first two

230

measurements was observed, a third measurement was taken and the middle value of the three

231

measurements was used.

232

Biochemical analyses

233

Fasting (≥12 hours) blood, saliva, and urine samples were collected pre- and post-treatment.

234

Blood samples were collected by venepuncture into EDTA and Lithium Heparin Plasma with
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Gel (LH PST II) tubes. Whole blood was centrifuged at 4⁰C, 3500 rpm for 10 minutes and

236

plasma aliquots stored at -80⁰C until analysis. Participants spat into sterile polystyrene jars for

237

5 minutes to obtain saliva samples and saliva aliquots stored at -80°C until analysis. Spot

238

urine samples were also collected into sterile polystyrene jars and aliquots stored at -80°C

239

until analysis.

240

Nitrate and nitrite analysis

241

Nitrate and nitrite concentrations were measured in plasma, saliva, urine, and juice samples

242

using gas chromatography/mass spectrometry (GCMS) with 15N-labelled nitrate and nitrite as

243

internal standards, as previously described (27).

244

Plasma carotenoid analysis

245

High-performance liquid chromatography (HPLC) methodology was used to determine

246

plasma carotenoid concentrations of β-carotene, lycopene, α-carotene, β-cryptoxanthin, and

247

lutein/ zeaxanthin, as previously described (28). Carotenoids were extracted using ethanol,

248

ethyl acetate, and hexane, with canthaxanthin as an internal standard. Following evaporation

249

of the solvents, the dried extract was reconstituted in dichloromethane: methanol (1:2 /vol)

250

and chromatography performed on an Agilent 1200 HPLC system using Hypersil ODS

251

column (100 mm X 2.1 mm X 5 um). Carotenoids were analysed using a mobile phase of

252

acetonitrile: dichloromethane: methanol 0.05% ammonium acetate (85:10:5 v/v) at a flow rate

253

of 0.3 mL/min, using a diode array detector (450 nm).

254

Other biochemical analyses

255

Urinary concentrations of sodium, potassium, and creatinine as well as plasma concentrations

256

of sodium, potassium, creatinine, glucose, total cholesterol, high-density lipoprotein (HDL)

257

cholesterol, triglycerides, and calculated low-density lipoprotein (LDL) cholesterol were

258

analysed by PathWest laboratories (Fiona Stanley Hospital, Perth, Australia).

259

Statistics
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Sample size

261

The required sample size for the study was based on the primary outcome of blood pressure

262

measured using 24-hour ambulatory monitoring. It was estimated 25 participants would

263

provide >80% power to detect a 2.0 mmHg difference in mean 24-hour systolic blood

264

pressure, based on data from our previous studies (29, 30). This calculation assumes a type I

265

error rate of 0.05/3 (0.017). In addition, we had >80% power to detect a 2.0 mmHg difference

266

in mean home systolic blood pressure, based on data from our previous studies (29, 30).

267

Statistical methods

268

Global statistical significance was set at a 2-sided Type 1 error rate of P<0.05. All data were

269

analysed using IBM SPSS Statistics for Windows, version 21.0 (IBM) and SAS software,

270

version 9.4 (SAS Institute Inc.). Normality of distributions was tested using the Shapiro-Wilk

271

normality test. Descriptive statistics of normally distributed continuous variables were

272

expressed as mean ± standard deviation (SD), non-normally distributed continuous variables

273

were expressed as median and interquartile range, and categorical variables as number and

274

proportion (%). Differences between treatments (high nitrate, low nitrate, and control) were

275

tested for each outcome variable using a repeated measures mixed model (proc mixed

276

command) with additional adjustments for outcome pre-treatment values, treatment period

277

and treatment order. We tested for any carryover effects between treatment periods using a

278

treatment*treatment period interaction term.
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RESULTS

280

Recruitment began on 25 May 2015 and final data was collected on 5 May 2016. Of the 65

281

participants screened for the study, 32 participants were randomised of whom 30 completed

282

the study. Two participants withdrew after randomisation due to medical reasons unrelated to

283

the trial (Figure 1).

284

Baseline demographic and clinical characteristics for the 30 participants are shown in Table

285

1. Baseline dietary data is shown in Supplemental Table 4. At baseline, the mean (SD) total

286

nitrate, estimated using a nitrate content of vegetables database (31) as well as published food

287

composition data, was 84.7 (36.2) mg/d (81.9% from vegetables alone). The mean (SD) total

288

vegetable intake was 181.8 (75.8) g/d. Using participants’ food diaries from each treatment

289

period, the median (IQR) reported increase in nitrate-rich vegetables for the high nitrate

290

treatment was 201.5 (198.7-204.1) g/d and the increase in nitrate-poor vegetables for the low

291

nitrate treatment was 201.7 (197.0-207.7) g/d. Descriptive statistics for the individual nitrate-

292

rich and nitrate-poor vegetables consumed in both the high and low nitrate treatments are

293

shown in Supplemental Table 3. The median (IQR) nitrate and nitrite concentrations, from

294

the juice samples provided by participants, and in which the participants were estimated to be

295

consuming, were: 149.1 (118.2-237.0) and 3.96 (2.19-5.20) mg/d for the high nitrate

296

treatment (n=30); 21.5 (13.9-29.9) and 0.31 (0.16-0.48) mg/d for the low nitrate treatment

297

(n=27); and 5.5 (3.7-8.0) and 0.06 (0.05-0.08) mg/d for the control (n=29), respectively.

298

Nitrate and nitrite concentrations were significantly different between treatment juices

299

(P<0.001 for both). High nitrate juices were 27-fold higher in nitrate and 66-fold higher in

300

nitrite concentration than that of the control (P<0.001 for both). In addition, the high nitrate

301

juices were 6.9-fold higher in nitrate and 12.8-fold higher in nitrite concentration than that of

302

the low nitrate juices (P<0.001 for both). The low nitrate and control juices were not different

303

in nitrate (P=0.326) and nitrite (P=0.779) concentrations.
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Compliance

305

Compliance was measured for the three treatments using self-reported food diaries.

306

Participants recorded the weight (g) of each vegetable consumed in their juice on a daily

307

basis. Compliance was calculated by dividing the number of days the vegetables were

308

consumed by the number of days the vegetables should have been consumed and then

309

multiplying by 100. On the basis of reported consumption of treatments using food diaries,

310

the median (IQR) compliance was 98.1 (90.6-100.0%) for the high nitrate treatment, 98.1%

311

(92.9-100.0%) for the low nitrate treatment, and 98.1% (96.0-100.0%) for the control

312

treatment. Compliance for the control diet was also measured by dividing the amount (g) of

313

returned maltodextrin by the amount (g) of maltodextrin administered to participants before

314

their treatment period and then multiplying by 100. On the basis of returned maltodextrin, the

315

median (IQR) compliance was 131.5% (110.7-142.5%). All treatment diets were well

316

tolerated. Whilst on the control treatment, one participant reported constipation symptoms and

317

another reported loose stools. No serious adverse events were reported.

318

Biomarkers of intake and metabolism

319

Plasma nitrate and nitrite

320

Median (IQR) plasma nitrate and nitrite concentrations pre- and post-treatment are shown in

321

Table 2. Plasma nitrate was significantly different between treatments (P<0.001) (Figure 2).

322

There was a 1.7-fold increase in plasma nitrate concentrations for the high nitrate treatment

323

compared to the low nitrate treatment (P<0.001) and a 1.6-fold increase for the high nitrate

324

treatment compared to control (P<0.001) (Figure 2). Plasma nitrite was significantly different

325

between treatments (P=0.007) (Figure 2). There was a 1.5-fold increase in plasma nitrite

326

concentrations for the high nitrate treatment compared to the low nitrate treatment (P=0.002)

327

and a 1.3-fold increase for the high nitrate treatment compared to control (P=0.037) (Figure

328

2).
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Salivary nitrate and nitrite

330

Median (IQR) salivary nitrate and nitrite concentrations for pre- and post-treatment are shown

331

in Table 2. Salivary nitrate was significantly different between treatments (P=0.038) (Figure

332

2). There was a 1.7-fold increase in salivary nitrate concentrations for the high nitrate

333

treatment compared to the low nitrate treatment (P=0.022) and a 1.6-fold increase for the high

334

nitrate treatment compared to control (P=0.036) (Figure 2). Salivary nitrite was not

335

significantly different between treatments (P=0.098) (Figure 2).

336

Urinary nitrate and nitrite

337

Median (IQR) urinary nitrate and nitrite concentrations adjusted for urinary creatinine are

338

presented in Table 2. Urinary nitrate was significantly different between treatments (P<0.001)

339

(Figure 2). There was a 1.9-fold increase in urinary nitrate concentration for the high nitrate

340

treatment compared to the low nitrate treatment (P<0.001) and a 1.8-fold increase for the high

341

nitrate treatment compared to the control (P<0.001) (Figure 2). Urinary nitrite was not

342

significantly different between treatments (P=0.074) (Figure 2).

343

Plasma carotenoids

344

Descriptive statistics for plasma total carotenoids, lutein, beta-cryptoxanthin, lycopene, alpha-

345

carotene, and beta-carotene are presented in Table 3. Plasma total carotenoids were

346

significantly different between treatments (P<0.001) (Figure 3). There was a 1.4-fold increase

347

in the high nitrate treatment compared to the control (P<0.001) and a 1.3-fold increase in the

348

low nitrate treatment compared to the control (P=0.002) (Figure 3). Plasma lutein was

349

significantly different between treatments (P<0.001) (Figure 3). There was a 1.6-fold increase

350

in plasma lutein in the high nitrate treatment compared to the low nitrate treatment (P<0.001)

351

and a 1.8-fold increase in the high nitrate treatment compared to the control (P<0.001) (Figure

352

3). Plasma beta-carotene was significantly different between treatments (P=0.002) (Figure 3).

353

There was a 1.6-fold increase in plasma beta-carotene in the high nitrate treatment compared
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to the control (P=0.002) and a 1.6-fold increase in the low nitrate treatment compared to the

355

control (P=0.003) (Figure 3). Plasma beta-cryptoxanthin, lycopene, and alpha-carotene were

356

not significantly different between treatments (Figure 3).

357

Plasma and urinary sodium and potassium

358

Plasma and urinary sodium and potassium, and urinary sodium to potassium ratio were not

359

significantly different between treatments (Table 4).

360

Blood pressure

361

Ambulatory blood pressure

362

Ambulatory measures of blood pressure were excluded for 2 (6.7%) participants due to

363

equipment malfunction (n=1) and <70% successful readings (n=1). The mean (SD) 24-hour,

364

daytime, and night-time ambulatory measures of blood pressure and heart rate pre- and post-

365

treatment are presented in Table 5. There were no significant differences between treatments

366

for mean 24-hour, daytime, or night-time ambulatory blood pressure and heart rate (Figure

367

4). No carryover effects were observed for 24-hour, daytime, and night-time ambulatory

368

measures of blood pressure and heart rate (P>0.05 for all). In a post-hoc sensitivity analysis in

369

which we adjusted for age, gender and BMI, the results were very similar and not

370

substantively changed (data not shown).

371

Home blood pressure

372

Home measures of blood pressure were complete for all participants. Mean (SD) home

373

measures of blood pressure and heart rate pre- and post-treatment are presented in Table 5.

374

There were no significant differences between treatments for blood pressure and heart rate for

375

the last 7 days of treatment (Figure 4). There were also no significant differences between

376

treatments for blood pressure and heart rate for week 1, week 2 and week 3 of treatment when

377

analysed separately (Figure 5). In addition, we found no significant differences between

378

treatments for blood pressure and heart rate measured in the morning, afternoon, and evening
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when analysed separately (data not shown). Mean daily home measures of blood pressure and

380

heart rate are shown in Supplemental Figure 2. No carryover effects were observed for

381

home measures of blood pressure and heart rate (P>0.05 for all).

382

Clinic blood pressure

383

Clinic measures of blood pressure were complete for all participants. Mean (SD) clinic

384

measures of blood pressure and heart rate pre- and post-treatment are presented in Table 5.

385

There were no significant differences between treatments for blood pressure and heart rate

386

(Figure 4).

387

Arterial stiffness

388

Pulse wave analysis was complete for all participants. Pulse wave velocity was incomplete for

389

4 (13.3%) participants due to an inability to obtain measurements. Mean (SD) central systolic

390

and diastolic pressures, central augmentation index (%), and pulse wave velocity for pre- and

391

post-treatment are shown in Table 6. No significant differences were observed between

392

treatments for central systolic blood pressure, central diastolic blood pressure, central

393

augmentation index, and pulse wave velocity.

394

Plasma lipids and glucose

395

Plasma total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, and glucose were

396

not significantly different between treatments (Table 4).

397

Anthropometry, physical activity and alcohol intake

398

Descriptive statistics for anthropometry, physical activity, and alcohol intake pre- and post-

399

treatment are presented in Supplemental Table 5. Weight, BMI, waist circumference, hip

400

circumference, and waist-to-hip ratio were not significantly different between treatments.

401

Physical activity expended in kJ/d and alcohol consumed in the last 7 days prior to each

402

treatment period were also not significantly different between treatments.
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DISCUSSION

404

In this 4-week randomised controlled crossover trial, an additional ~200 g/d intake of nitrate-

405

rich vegetables did not alter blood pressure or arterial stiffness in men and women with pre-

406

hypertension or untreated grade 1 hypertension. There was a significant increase in salivary,

407

urinary, and plasma nitrate as well as plasma nitrite concentrations after the high nitrate

408

treatment, confirming the dietary interventions were effective in altering nitrate

409

concentrations. In addition, total plasma carotenoids were increased with increased

410

consumption of both high and low nitrate vegetables. Our study findings did not support our

411

hypothesis that an increased intake of high nitrate vegetables would result in lower blood

412

pressure and improved arterial stiffness.

413

A number of short-term trials have assessed the effects of increased nitrate intake on blood

414

pressure (10, 11). The results of these studies are inconsistent, with several trials finding

415

lower blood pressure with increased nitrate intake (19, 32-37), and others finding no effect

416

(20, 38-42). Our study is unique in that the design assessed the impact of a sustained 4-week

417

increase in nitrate-rich vegetables in individuals with pre-hypertension or untreated grade 1

418

hypertension and that subjects were not taking anti-hypertensive medication which could have

419

modified any effect of nitrate. There are many potential factors that could influence whether

420

an increase in nitrate intake results in lower blood pressure. The duration of the study appears

421

to be a factor, with acute studies consistently showing blood pressure lowering effects (17,

422

42-53). Other factors may include the dose of nitrate provided; the background nitrate and

423

vegetable intake of the study participants, which may alter the effective dose; whether there is

424

an individual threshold level, beyond which there is little additional benefit; and the age and

425

health status of the participants.

426

Only three studies have investigated the short-term sustained effects of nitrate ingestion on

427

blood pressure and arterial stiffness over a period of four or more weeks (19, 33, 42). Of
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these, only one has investigated the effects in pre-hypertensive or untreated hypertensive

429

individuals (19). Kapil et al (19) found daily consumption of beetroot juice (nitrate dose: 398

430

mg/d or 6.4 mmol/d) reduced blood pressure and improved arterial stiffness in 64 untreated or

431

treated hypertensive individuals. Although our study does not align with the aforementioned

432

study (19), other short-term intervention studies (3-42 days) have demonstrated no effect of

433

nitrate ingestion on blood pressure (20, 38-42) or arterial stiffness (40, 41). These studies

434

were all in individuals at risk for cardiovascular disease (20, 38-42). Previous trials where

435

improvements have been observed in blood pressure and arterial stiffness with increased

436

nitrate intake have been a mix of healthy participants (34-37) and those at risk of

437

cardiovascular disease (19, 32, 33, 42). There is strong evidence to show that nitrate ingestion

438

reduces blood pressure within hours of ingestion (17, 42-53). The acute effects on arterial

439

stiffness are less clear. Some studies demonstrate improvements (42, 44, 53) while others do

440

not (47, 50, 51, 54).

441

Several factors may explain why our study did not demonstrate a reduction in blood pressure.

442

As mentioned previously, background diet may have influenced nitrate metabolism with

443

individuals having sufficient nitrate intake unresponsive to further nitrate supplementation.

444

Possible interactions between nitrate and sulphur-containing dietary constituents have been

445

proposed (55). Nitrate in drinking water was inversely associated with blood pressure at low

446

sulphate concentrations (9-33 mg/L), but this relationship reversed at medium to high

447

concentrations (34-102 mg/L). Such an interaction would unlikely to have confounded the

448

results of our study as the calculated mean sulphate concentration in water consumed by our

449

cohort was 13.5 mg/L (data not shown). This data, however, does not fully discount such an

450

interaction as sulphur-containing foods within the diet cannot be calculated due to the absence

451

of adequate nutrient databases. In addition, Montenegro et al (56) has recently demonstrated

452

acid suppressing drugs abolished the blood pressure lowering effects of oral nitrite ingestion
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453

despite the increase in plasma nitrite concentration. Only one participant in our study reported

454

taking an acid suppressing drug (Rabeprazole) for the treatment of gout. This does not

455

discount the theory that gastric pH may differ between individuals and that it is a possible

456

determinant in influencing blood pressure after nitrate ingestion.

457

Limitations to this intervention study need to be considered. Firstly, we did not observe

458

differences in urinary potassium concentrations. We may have expected to see a >10%

459

increase in potassium excretion given the self-reported increases in vegetable intake. This

460

could be the result of using creatinine-adjusted values from a spot urine instead of a 24-hour

461

urine sample to assess urinary potassium (57). We did, however, observe a ~1.6 fold increase

462

in plasma nitrate and nitrite with increased nitrate-rich vegetables and a ~1.4 fold increase in

463

plasma total carotenoids with increased nitrate-rich and nitrate-poor vegetables. The increase

464

in plasma nitrate, nitrite, and total carotenoids gives us confidence the participants were

465

compliant. It should be noted that plasma nitrite concentrations in our study are higher than

466

some reported values in the literature. This could be due to a number of factors; however, it is

467

likely an outcome of the GCMS method compared to gas phase chemiluminescence (27).

468

Secondly, our study demonstrated no statistical difference in salivary and urinary nitrite

469

concentrations. Circulating nitrate and nitrite concentrations depend on when nitrate is last

470

ingested. The half-life of nitrate in plasma is 5-6 hours (58). Nitrite is likely to be similar as

471

new nitrite is being continuously generated from the ingested nitrate. As participants were

472

asked to fast for at least 12 hours prior to providing samples, this may explain why no

473

increases in salivary and urinary nitrite concentrations were observed. However, other

474

mechanisms may explain this observation and warrants further investigation. Thirdly, the

475

estimated nitrate intake from the measured juice samples was 149 mg/d, whereas the

476

estimated nitrate intake using a comprehensive international nitrate database (31) was 326

477

mg/d. The nitrate content of vegetables available in Perth may be appreciably lower than
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many other regions of the world due to high intensity of sunlight and longer daylight hours.

479

Vegetables grown in lower light intensity and fewer daylight hours have a tendency to

480

accumulate higher nitrate concentrations (59, 60). Fourthly, due to the nature of the

481

intervention, participants could not be blinded to the treatments received. Blinding was,

482

however, utilised for all laboratory analyses. Lastly, we cannot rule out any small effects on

483

blood pressure, less than approximately 2 mmHg.

484

In summary, our findings suggest no short-term clinically significant effects on blood

485

pressure, arterial stiffness, lipids and glucose from increasing the intake of nitrate-rich

486

vegetables in men and women with pre-hypertension or untreated grade 1 hypertension. There

487

are likely complex issues surrounding why no benefit was seen, including background nitrate

488

intake, the level of increase in nitrate intake, cross-talk mechanisms and populations at risk of

489

cardiovascular disease, which may all play a vital role in the differences observed between

490

studies.
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Table 1. Demographic and clinical characteristics of study participants at screening1
All participants
n = 30
Demographics
Male/female, n
20/10
Age, years
63.0 [55.5-70.5]
2
BMI, kg/m
27.0 ± 3.9
2
Waist circumference , cm
89.5 ± 11.7
2
Hip circumference , cm
102.0 [95.0-104.5]
2
Waist-to-hip ratio
0.9 ± 0.1
2
Smoking history
11 (37.9)
Medications
HMG-CoA reductase inhibitors
5 (16.7)
Clinic blood pressure
Systolic blood pressure, mmHg
133.6 ± 8.4
Diastolic blood pressure, mmHg
77.7 ± 8.0
Heart rate, bpm
61.6 ± 8.0
Biochemistry
Total cholesterol, mmol/L
5.5 [4.3-6.3]
Triglycerides, mmol/L
1.2 [0.8-1.7]
LDL cholesterol, mmol/L
3.6 ± 1.2
HDL cholesterol, mmol/L
1.3 ± 0.3
Glucose, mmol/L
5.3 ± 0.4
1
Results are displayed as mean ± SD, median [IQR] or n (%). BMI, body mass index;
LDL, low density lipoprotein; HDL, high density lipoprotein.
2
n=29.
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Table 2. Descriptive statistics for nitrate and nitrite concentrations in plasma, saliva and urine by treatment, and the between-treatment
differences1
Treatment effect2
C
LN
HN
(n=30)
(n=30)
(n=30)
HN vs. C
HN vs. LN
Nitrate
Plasma, µmol/L
Pre
22.4 [17.5-27.5]
23.5 [18.7-28.3]
23.0 [16.2-32.6]
Post
22.5 [19.0-30.2]
22.7 [15.2-27.2]
34.3 [26.1-52.1]
15.8 ± 4.13
16.7 ± 4.33
Salivary, µmol/L
Pre
126.4 [48.5-194.1]
116.1 [35.8-197.3]
94.1 [38.1-152.4]
Post
107.9 [39.3-214.7]
75.6 [36.1-190.1]
134.8 [33.2-341.6]
91.5 ± 42.64
102.4 ± 43.34
Urinary, µmol/mmol creatinine
Pre
48.8 [28.6-63.9]
38.2 [28.1-58.0]
42.9 [29.0-62.6]
Post
47.4 [30.2-73.5]
44.4 [29.7-58.4]
79.4 [47.8-138.8]
39.5 ± 10.73
43.0 ± 11.23
Nitrite
Plasma, µmol/L
Pre
2.1 [1.6-2.9]
2.1 [1.6-2.7]
2.3 [1.7-2.7]
Post
2.4 [1.9-3.2]
2.0 [1.4-2.5]
2.8 [2.2-4.2]
0.7 ± 0.34
1.1 ± 0.34
Salivary, µmol/L
Pre
53.9 [17.0-112.0]
48.7 [18.9-101.0]
36.8 [15.0-67.8]
Post
61.0 [25.6-90.9]
41.9 [12.5-92.1]
67.0 [16.1-157.1]
29.5 ± 19.9
42.6 ± 20.04
Urinary, µmol/mmol creatinine
Pre
6.7 [2.7-16.3]
9.3 [2.9-16.6]
8.2 [3.9-18.0]
Post
9.1 [4.1-18.0]
13.8 [3.2-22.9]
13.0 [3.5-38.0]
8.6 ± 3.84
6.4 ± 4.0
1
Results are presented as median [IQR]. n=30. C, control; LN, low nitrate; HN, high nitrate.
2
Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C)
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling.
3
P<0.001.

34
4

P<0.05.
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Table 3. Descriptive statistics for plasma carotenoid concentrations by treatment, and the between-treatment differences1
C
(n=30)

LN
(n=30)2

HN
(n=30)

Treatment effect3
HN vs. C
HN vs. LN

Total carotenoids, mg/L
Pre
1.675 [1.200-2.212]
1.711 [1.360-2.457]
1.701 [1.305-2.205]
Post
1.613 [1.257-2.217]
1.850 [1.524-2.668]
2.131 [1.637-2.560]
0.658 ± 0.1704
0.073 ± 0.178
Lutein, mg/L
Pre
0.316 ± 0.107
0.321 ± 0.114
0.303 ± 0.102
Post
0.313 ± 0.120
0.355 ± 0.120
0.547 ± 0.176
0.246 ± 0.0275 0.202 ± 0.0295
Beta-cryptoxanthin, mg/L
Pre
0.337 [0.269-0.539]
0.387 [0.272-0.506]
0.361 [0.249-0.551]
Post
0.385 [0.292-0.504]
0.406 [0.310-0.736]
0.362 [0.306-0.547]
-0.067 ± 0.047 -0.098 ± 0.049
Lycopene, mg/L
Pre
0.036 [0.018-0.067]
0.041 [0.023-0.081]
0.042 [0.021-0.075]
Post
0.033 [0.023-0.065]
0.052 [0.018-0.084]
0.037 [0.022-0.069]
-0.002 ± 0.005
0.010 ± 0.006
Alpha-carotene, mg/L
Pre
0.047 [0.027-0.076]
0.047 [0.024-0.086]
0.056 [0.032-0.086]
Post
0.053 [0.033-0.081]
0.057 [0.027-0.089]
0.051 [0.023-0.071]
-0.008 ± 0.006 -0.011 ± 0.006
Beta-carotene, mg/L
Pre
0.797 [0.317-1.149]
0.781 [0.443-1.399]
0.737 [0.535-1.144]
Post
0.787 [0.365-1.040]
0.925 [0.528-1.602]
1.158 [0.630-1.460]
0.438 ± 0.1376
0.010 ± 0.144
1
Results are presented as mean ± SD or median [IQR]. n=30. C, control; LN, low nitrate; HN, high nitrate.
2
Low nitrate post treatment (n=29).
3
Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C)
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling.
4
P<0.001.
5
P<0.0001.
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P<0.01

37

Table 4. Descriptive statistics for standard biochemical analyses by treatment, and the between-treatment differences1

Plasma total cholesterol,
mmol/L
Pre
Post
Plasma triglycerides, mmol/L
Pre
Post
Plasma LDL cholesterol,
mmol/L
Pre
Post
Plasma HDL cholesterol,
mmol/L
Pre
Post
Plasma glucose, mmol/L
Pre
Post
Plasma creatinine, mmol/L
Pre
Post
Plasma sodium, mmol/L
Pre
Post

Treatment effect2
HN vs. C
HN vs. LN

C
(n=30)

LN
(n=30)

HN
(n=30)

5.5 ± 1.0
5.6 ± 1.3

5.5 ± 1.2
5.5 ± 1.2

5.5 ± 1.2
5.3 ± 1.1

-0.33 ± 0.14

-0.23 ± 0.14

1.0 [0.9-1.5]
1.1 [0.9-1.6]

1.1 [0.8-1.7]
1.2 [0.9-1.8]

1.1 [0.8-1.4]
1.0 [0.7-1.6]

-0.10 ± 0.07

0.14 ± 0.07

3.4 ± 0.9
3.6 ± 1.1

3.4 ± 1.0
3.5 ± 1.1

3.5 ± 1.1
3.4 ± 1.0

-0.25 ± 0.12

0.15 ± 0.13

1.5 ± 0.4
1.4 ± 0.4

1.4 ± 0.4
1.4 ± 0.4

1.4 ± 0.3
1.4 ± 0.4

-0.03 ± 0.03

-0.03 ± 0.03

5.1 ± 0.5
5.0 ± 0.4

4.9 ± 0.4
5.0 ± 0.4

5.0 ± 0.6
5.0 ± 0.5

0.01 ± 0.08

-0.01 ± 0.08

69.9 ± 10.1
70.5 ± 10.0

70.5 ± 10.6
71.2 ± 11.2

70.1 ± 12.1
69.2 ± 10.0

-1.35 ± 1.31

-2.14 ± 1.37

137.0 [134.5-138.7]
137.5 [134.9-138.9]

137.3 [135.6-138.1]
137.0 [135.7-138.1]

137.0 [134.9-138.9]
136.2 [133.3-138.4]

-0.12 ± 1.2

-0.05 ± 1.29
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Plasma potassium, mmol/L
Pre
4.1 ± 0.3
4.0 ± 0.3
4.0 ± 0.3
Post
4.0 ± 0.3
4.0 ± 0.3
3.9 ± 0.3
-0.07 ± 0.06
-0.03 ± 0.06
Urinary sodium, mmol/mmol
creatinine
Pre
8.2 [5.0-10.8]
8.3 [5.5-12.7]
8.9 [4.4-11.1]
Post
7.0 [4.7-11.3]
8.0 [6.6-11.1]
7.1 [5.3-10.5]
0.44 ± 1.05
-0.70 ± 1.10
Urinary potassium,
mmol/mmol creatinine
Pre
7.3 [5.9-8.7]
7.4 [5.9-10.0]
7.8 [5.6-10.1]
Post
8.1 [7.1-9.3]
7.8 [5.9-9.8]
8.1 [6.5-10.4]
0.22 ± 0.54
0.35 ± 0.56
Urinary sodium/potassium
ratio, mmol/mmol creatinine
Pre
1.0 [0.8-1.5]
1.1 [0.8-1.5]
0.9 [0.6-1.5]
Post
0.8 [0.6-1.3]
1.0 [0.8-1.5]
0.9 [0.6-1.3]
0.07 ± 0.11
0.12 ± 0.12
1
Results are presented as mean ± SD or median [IQR]. n=30. C, control; LN, low nitrate; HN, high nitrate.
2
Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C)
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. There were no
significant differences between treatments.
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Table 5. Descriptive statistics for blood pressure by treatment, and the between-treatment differences1
C
LN
HN
(n=30)
(n=30)
(n=30)
3
Ambulatory blood pressure
Overall 24-hour
SBP mean, mmHg
Pre
126.5 ± 7.8
126.6 ± 6.4
125.6 ± 6.8
Post
125.9 ± 7.4
127.9 ± 8.5
126.5 ± 6.1
DBP mean, mmHg
Pre
75.3 ± 8.6
75.3 ± 7.5
75.2 ± 7.8
Post
75.0 ± 8.3
75.7 ± 8.9
75.2 ± 7.9
HR mean, beats/min
Pre
68.0 ± 8.5
69.3 ± 8.5
68.8 ± 8.3
Post
68.2 ± 8.3
68.6 ± 8.2
68.6 ± 8.0
Day time
SBP mean, mmHg
Pre
130.4 ± 8.0
130.7 ± 6.7
129.8 ± 7.0
Post
130.2 ± 7.9
132.0 ± 9.0
130.6 ± 6.4
DBP mean, mmHg
Pre
78.4 ± 8.8
78.8 ± 7.9
78.5 ± 8.2
Post
78.3 ± 8.7
78.9 ± 9.4
78.4 ± 8.5
HR mean, beats/min
Pre
70.7 ± 9.3
72.3 ± 9.0
71.5 ± 8.7
Post
70.6 ± 8.9
71.5 ± 8.8
71.2 ± 8.6
Night time
SBP mean, mmHg
Pre
114.9 ± 9.4
113.5 ± 7.8
112.5 ± 8.5
Post
112.6 ± 8.4
115.3 ± 10.4
114.2 ± 8.9

Treatment effect2
HN vs. C
HN vs. LN

1.1 ± 1.3

-1.3 ± 1.3

0.4 ± 0.9

-0.6 ± 1.0

-0.2 ± 1.0

0.3 ± 1.0

0.7 ± 1.5

-1.3 ± 1.5

0.1 ± 1.1

-0.5 ± 1.1

-0.1 ± 1.1

0.3 ± 1.1

3.0 ± 1.7

-1.1 ± 1.7
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DBP mean, mmHg
Pre
Post
HR mean, beats/min
Pre
Post
Home blood pressure
Overall 4-week
SBP mean, mmHg
Pre
Post
DBP mean, mmHg
Pre
Post
HR mean, beats/min
Pre
Post
Clinic blood pressure
SBP mean, mmHg
Pre
Post
DBP mean, mmHg
Pre
Post
HR mean, beats/min
Pre
Post

66.0 ± 8.8
64.8 ± 8.0

64.7 ± 7.4
66.0 ± 8.8

65.3 ± 8.1
65.5 ± 7.9

1.0 ± 1.0

-1.0 ± 1.1

60.0 ± 7.6
60.7 ± 7.7

60.1 ± 7.6
59.7 ± 7.6

60.5 ± 8.2
60.7 ± 7.3

-0.4 ± 1.1

0.4 ± 1.2

128.2 ± 10.2
128.0 ± 9.5

126.9 ± 9.9
126.9 ± 10.0

129.3 ± 10.1
127.8 ± 9.7

-0.9 ± 0.7

-1.3 ± 0.8

75.1 ± 8.8
75.3 ± 8.6

74.5 ± 8.6
74.5 ± 9.0

75.6 ± 9.0
74.5 ± 8.9

-0.6 ± 0.6

-1.2 ± 0.6

64.6 ± 8.8
65.1 ± 8.6

65.2 ± 9.0
64.9 ± 8.8

65.5 ± 8.9
65.7 ± 8.3

-0.2 ± 0.5

0.6 ± 0.6

130.4 ± 8.6
130.0 ± 7.6

129.8 ± 10.0
129.7 ± 8.4

130.2 ± 7.8
128.4 ± 8.9

-1.4 ± 1.6

-1.9 ± 1.7

77.4 ± 7.1
76.5 ± 5.7

75.2 ± 7.6
76.2 ± 8.4

76.6 ± 7.0
75.3 ± 7.2

-0.6 ± 1.0

-2.3 ± 1.1

57.2 ± 7.5
56.9 ± 7.3

56.3 ± 7.9
56.9 ± 7.6

57.9 ± 8.0
58.3 ± 8.1

-0.5 ± 1.0

-0.2 ± 1.1
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1

Results are presented as mean ± SD. n=30. C, control; LN, low nitrate; HN, high nitrate; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HR, heart rate.
2
Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C)
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. Home blood
pressure pre-treatment values that were adjusted for were the last 7 days prior to treatment. There were no significant differences between
treatments.
3
n=28.
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Table 6. Descriptive statistics for pulse wave analysis and pulse wave velocity results by treatment, and the between-treatment differences1
C
LN
HN
Treatment effect2
(n=30)
(n=30)
(n=30)
HN vs. C
HN vs. LN
Central systolic pressure, mmHg
Pre
119.8 ± 8.7
118.9 ± 10.2
118.8 ± 7.8
Post
119.1 ± 8.1
118.7 ± 8.6
117.8 ± 9.1
-0.6 ± 1.5
-1.1 ± 1.5
Central diastolic pressure, mmHg
Pre
77.4 ± 7.2
75.4 ± 7.6
76.9 ± 7.1
Post
76.5 ± 5.3
76.3 ± 8.3
75.8 ± 7.4
-0.4 ± 1.0
-2.0 ± 1.1
Central augmentation index, %
Pre
29.5 ± 11.2
27.6 ± 10.5
29.3 ± 11.4
Post
29.8 ± 10.2
28.5 ± 10.9
28.8 ± 10.0
-0.7 ± 1.3
0.7 ± 1.4
3
Pulse wave velocity , m/s
Pre
8.2 ± 1.5
8.3 ± 1.1
8.3 ± 1.1
Post
8.3 ± 1.3
8.3 ± 0.9
8.3 ± 1.1
-0.1 ± 0.1
-0.1 ± 0.1
1
Results are presented as mean ± SD. n=30. C, control; LN, low nitrate; HN, high nitrate.
2
Between-treatment differences are for the post-treatment values of the high nitrate (HN) compared with low nitrate (LN) and control (C)
treatments, adjusted for pre-treatment values, treatment period and treatment order using repeated measures mixed modelling. There were no
significant differences between treatments.
3
n=26.
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Figure 1. CONSORT flow diagram for participant recruitment.
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Figure 2. The effects of 4 weeks high and low nitrate vegetable juice on nitrate
concentrations in (A) plasma, (B) saliva, and (C) urine; and nitrite concentrations in (D)
plasma, (E) saliva, and (F) urine. Results are presented as estimated mean ± SE adjusted for
pre-treatment values, treatment period and treatment order using repeated measures mixed
modelling (n=30).
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Figure 3. The effects of 4 weeks high and low nitrate vegetable juice on plasma
concentrations of (A) total carotenoids, (B) lutein, (C) beta-cryptoxanthin, (D) lycopene, (E)
alpha-carotene and (F) beta-carotene. Results are presented as estimated mean ± SE adjusted
for pre-treatment values, treatment period and treatment order using repeated measures mixed
modelling (n=30). Low nitrate treatment (n=29).
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Figure 4. The effects of 4 weeks high and low nitrate vegetable juice on ambulatory, home
and clinic measures of (A) systolic blood pressure, (B) diastolic blood pressure, and (C) heart
rate. Results are presented as estimated mean ± SE adjusted for pre-treatment values,
treatment period and treatment order using repeated measures mixed modelling. There were
no significant differences between treatments. Home measures of blood pressure consisted of
the last 7 days of treatment adjusted for the 7 days prior to pre-treatment. Ambulatory blood
pressure (n=28); home and clinic blood pressure (n=30). C, control; L, low nitrate; H, high
nitrate.
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Figure 5. The effects of high and low nitrate vegetable juice on home measures of (A)
systolic blood pressure, (B) diastolic blood pressure, and (C) heart rate for week 1, week 2,
and week 3. Results are presented as estimated mean ± SE adjusted for the 7 days prior to pretreatment, treatment period and treatment order using repeated measures mixed modelling
(n=30). There were no significant differences between treatments.

